JP2024516320A - Fc受容体への結合が改変されたFc変異体 - Google Patents

Fc受容体への結合が改変されたFc変異体 Download PDF

Info

Publication number
JP2024516320A
JP2024516320A JP2023568549A JP2023568549A JP2024516320A JP 2024516320 A JP2024516320 A JP 2024516320A JP 2023568549 A JP2023568549 A JP 2023568549A JP 2023568549 A JP2023568549 A JP 2023568549A JP 2024516320 A JP2024516320 A JP 2024516320A
Authority
JP
Japan
Prior art keywords
seq
sequence
set forth
index
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516320A5 (cg-RX-API-DMAC7.html
Inventor
フォンケン フー
ショアイシアン チョウ
チーハイ ウー
Original Assignee
イノベント バイオロジクス(スーチョウ)カンパニー,リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イノベント バイオロジクス(スーチョウ)カンパニー,リミティド filed Critical イノベント バイオロジクス(スーチョウ)カンパニー,リミティド
Publication of JP2024516320A publication Critical patent/JP2024516320A/ja
Publication of JP2024516320A5 publication Critical patent/JP2024516320A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023568549A 2021-05-07 2022-05-06 Fc受容体への結合が改変されたFc変異体 Pending JP2024516320A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202110495363 2021-05-07
CN202110495363.7 2021-05-07
CN202210436873 2022-04-25
CN202210436873.1 2022-04-25
PCT/CN2022/091187 WO2022233320A1 (zh) 2021-05-07 2022-05-06 与Fc受体结合改变的Fc突变体

Publications (2)

Publication Number Publication Date
JP2024516320A true JP2024516320A (ja) 2024-04-12
JP2024516320A5 JP2024516320A5 (cg-RX-API-DMAC7.html) 2025-05-12

Family

ID=83932014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568549A Pending JP2024516320A (ja) 2021-05-07 2022-05-06 Fc受容体への結合が改変されたFc変異体

Country Status (8)

Country Link
US (1) US20240228579A1 (cg-RX-API-DMAC7.html)
EP (1) EP4335868A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024516320A (cg-RX-API-DMAC7.html)
CN (1) CN117295760A (cg-RX-API-DMAC7.html)
AU (1) AU2022269145B2 (cg-RX-API-DMAC7.html)
CA (1) CA3218187A1 (cg-RX-API-DMAC7.html)
TW (1) TWI839729B (cg-RX-API-DMAC7.html)
WO (1) WO2022233320A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024333211A1 (en) * 2023-08-30 2026-03-19 Astellas Pharma Inc. Fc REGION VARIANT

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008505174A (ja) * 2004-07-15 2008-02-21 ゼンコー・インコーポレイテッド 最適化Fc変異体
JP2019502698A (ja) * 2015-12-17 2019-01-31 ヤンセン バイオテツク,インコーポレーテツド Hla−drに特異的に結合する抗体及びその使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
TW201245227A (en) * 2011-03-29 2012-11-16 Roche Glycart Ag Antibody Fc variants
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
ES2597228T3 (es) * 2012-06-27 2017-01-17 F. Hoffmann-La Roche Ag Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
EP3494139B1 (en) * 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
US12024560B2 (en) * 2017-03-28 2024-07-02 Lyvgen Biopharma Holdings Limited Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
CN112912395B (zh) * 2018-08-20 2024-08-23 辉瑞公司 抗gdf15抗体、组合物和使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008505174A (ja) * 2004-07-15 2008-02-21 ゼンコー・インコーポレイテッド 最適化Fc変異体
JP2019502698A (ja) * 2015-12-17 2019-01-31 ヤンセン バイオテツク,インコーポレーテツド Hla−drに特異的に結合する抗体及びその使用

Also Published As

Publication number Publication date
WO2022233320A1 (zh) 2022-11-10
AU2022269145A1 (en) 2023-12-21
TWI839729B (zh) 2024-04-21
TW202246313A (zh) 2022-12-01
EP4335868A4 (en) 2025-08-13
CA3218187A1 (en) 2022-11-10
US20240228579A1 (en) 2024-07-11
EP4335868A1 (en) 2024-03-13
AU2022269145B2 (en) 2026-05-28
CN117295760A (zh) 2023-12-26

Similar Documents

Publication Publication Date Title
JP7264381B2 (ja) 血中半減期の向上のための抗体Fc変異体
CN116041516A (zh) 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用
CN111601821B (zh) 具有对FcRn的亲和力提高以及对至少一个Fc片段受体的亲和力提高的Fc片段的变体
KR20140014061A (ko) 항-huTNFR1 항체
JP2012515556A5 (cg-RX-API-DMAC7.html)
JP7842914B2 (ja) C5aRを標的とする抗体
JP2024505072A (ja) イヌ科動物抗体の定常領域における変異
AU2022404170A1 (en) Bispecific antibody and use thereof
CN121226555A (zh) 抗cMET抗体
CN121226557A (zh) 抗cMET抗体
CN121270705A (zh) 抗cMET抗体
CN116457374A (zh) 经修饰的可溶性t细胞受体
JP2025517120A (ja) アルブミン結合ポリペプチド及びその使用
CN115175736A (zh) 杂交抗体
TWI839729B (zh) 與Fc受體結合改變的Fc突變體
CN119698294A (zh) 结合γ-δT细胞受体的变体抗体
CN120590537A (zh) 靶向tigit的双特异性抗体
JP2024534034A (ja) 抗vegfr1抗体及びそれらの使用
CN116783220A (zh) 抗bcma抗体及其制备方法和应用
KR20250139314A (ko) 안티-pdl1 단일 도메인 항체, 융합 단백질 및 이의 용도
CN118530367A (zh) 一种靶向msln和4-1bb的双特异性抗体及其应用
JP2025519559A (ja) FcRn結合ポリペプチド及びその使用
WO2025185738A1 (zh) 靶向cxcr3的抗原结合蛋白及其应用
WO2025185656A1 (zh) 抗pd-l1和cd40双特异性抗体及其用途
KR20260007638A (ko) Cd3을 표적으로 하는 항체 또는 이의 항원 결합 단편 및 이의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260507